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Abstract
Oxysterols are oxidation products of cholesterol. Cholestane-3b, 5a, 6b-triol (abbreviated as triol) is one of the most
abundant and active oxysterols. Here, we report that triol exhibits anti-cancer activity against human prostate cancer cells.
Treatment of cells with triol dose-dependently suppressed proliferation of LNCaP CDXR-3, DU-145, and PC-3 human
prostate cancer cells and reduced colony formation in soft agar. Oral administration of triol at 20 mg/kg daily for three
weeks significantly retarded the growth of PC-3 xenografts in nude mice. Flow cytometric analysis revealed that triol
treatment at 10–40 mM caused G1 cell cycle arrest while the TUNEL assay indicated that triol treatment at 20–40 mM
induced apoptosis in all three cell lines. Micro-Western Arrays and traditional Western blotting methods indicated that triol
treatment resulted in reduced expression of Akt1, phospho-Akt Ser473, phospho-Akt Thr308, PDK1, c-Myc, and Skp2 protein
levels as well as accumulation of the cell cycle inhibitor p27Kip. Triol treatment also resulted in reduced Akt1 protein
expression in PC-3 xenografts. Overexpression of Skp2 in PC-3 cells partially rescued the growth inhibition caused by triol.
Triol treatment suppressed migration and invasion of DU-145, PC-3, and CDXR-3 cells. The expression levels of proteins
associated with epithelial-mesenchymal transition as well as focal adhesion kinase were affected by triol treatment in these
cells. Triol treatment caused increased expression of E-cadherin protein levels but decreased expression of N-cadherin,
vimentin, Slug, FAK, phospho-FAK Ser722, and phospho-FAK Tyr861 protein levels. Confocal laser microscopy revealed
redistribution of b-actin and a-tubulin at the periphery of the CDXR-3 and DU-145 cells. Our observations suggest that triol
may represent a promising therapeutic agent for advanced metastatic prostate cancer.
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Introduction
Prostate cancer is the second most frequently diagnosed cancer
of men and the fifth most common cancer overall in the world. In
2008, more than 899,000 new cases were diagnosed (GLOBO-
CAN 2008 database, version 1.2). In Western countries, prostate
cancer is the most common non-cutaneous carcinoma of men.
According to the statistics of Surveillance Epidemiology and End
Results (SEER) of the National Cancer Institute, more than
240,000 men were diagnosed with and more than 28,000 men
died of prostate cancer in 2012 in the United States. Although
surgery is often successful for organ-confined prostate cancer,
androgen ablation therapy is the primary treatment for metastatic
prostate cancer. Unfortunately, most prostate cancer patients
receiving androgen ablation therapy will ultimately develop
recurrent, castration-resistant tumors within 1–3 years after
treatment. The median overall survival time is 1–2 years after
cancer relapse [1,2]. No effective standard therapy exists for
patients that relapse with advanced prostate cancer. Chemother-
apy is often used to treat metastatic hormone-refractory prostate
cancer [2,3]. However, chemotherapies generally show little effect
on prolonging survival. Therefore, new treatments for advanced
prostate cancers are needed.
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Oxysterols are oxidation products of cholesterol. Oxysterols
play essential roles in regulating cholesterol homeostasis, platelet
aggregation, apoptosis, and protein prenylation [4]. However,
oxysterols are associated with development of atherosclerosis,
neurological disease, and cancers [4]. Certain oxysterols have been
reported to exhibit anticancer effects, possibly via modulation of
cholesterol efflux, Akt, or liver X receptors (LXRs) [5,6]. For
example, treatment with 22(R)-hydroxycholesterol, 24(S)-hydro-
xycholesterol, 7a-hydroxycholesterol, 7b-hydroxycholesterol, 25-
hydroxycholesterol, and 5a,6a-epoxycholesterol suppressed the
proliferation of human prostate, breast, colon, lung, and leukemia
cancer cells [7–14]. These oxysterols caused either G1 cell cycle
arrest [7–11] or apoptosis in cancer cells [12–14]. Therefore,
oxysterols with cytotoxic activity might be a potential therapeutic
agent for advanced prostate cancers.
Cholestane-3b, 5a, 6b-triol (abbreviated as triol) is one of the
most abundant oxysterols. Triol is derived from cholesterol by
oxidation via formation of 5a, 6a-epoxycholesterol and 5b, 6b-
epoxycholesterol [15,16] as intermediates. Previously, 5a, 6a-
epoxycholesterol was reported to exhibit anti-cancer activity [13].
In this study, we examined the ability of triol to suppress the
proliferation of advanced human prostate cancer cell lines both
in vitro and in vivo. We applied Micro-Western Arrays, a recently
developed antibody-based, high-throughput Western blotting
assay [17–20], to study the signaling proteins affected by triol in
advanced prostate cancer cells. Our observations suggested that
triol may represent a promising therapeutic agent for advanced
metastatic prostate cancer.
Materials and Methods
Materials
Cholestane-3b, 5a, 6b-triol was purchased from Sigma (St.
Louis, MO, USA). Matrigel was purchased from BD Bioscience
(San Jose, CA, USA).
Cell Culture
Prostate cancer cell lines PC-3, DU-145, and LNCaP sublines
were a gift from the laboratory of Professor Shutsung Liao (The
University of Chicago, IL, USA). These cell lines were previously
described [7,8,10,21–27]. LNCaP CDXR-3 cells were passaged
and maintained as described previously [7,8,10,11,21–23,27].
DU-145 and PC-3 cells were maintained in DMEM (Gibco/
Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal
bovine serum (FBS; Atlas Biologicals, Fort Collins, CO, USA),
penicillin (100 U/ml), and streptomycin (100 mg/ml) (complete
Figure 1. Effect of triol on viability and proliferation of human prostate cancer cell lines. LNCaP CDXR-3, DU-145, and PC-3 prostate
cancer cells were treated with increasing concentrations of triol for 48 hrs (A)(C) or 96 hrs (B)(D). Relative viability and relative cell number of prostate
cancer cells was determined by MTT (3,4,5-dimethylthiazol-2-yl)-2-5-diphenyltetrazolium bromide) 96-well assay (A)(B) and Hoechst dye 33258-based
96-well proliferation assay (C)(D), respectively, as described in Materials and Methods. Cell numbers were normalized to control (dimethylsulfoxide) of
each cell line. Asterisk (*, **, ***) represents statistically significant difference (p,0.05, p,0.01, p,0.001) between the treated group and the control
group.
doi:10.1371/journal.pone.0065734.g001
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medium) as previously described [28]. The PZ-HPV-7 cells were
purchased from Bioresource Collection and Research Center
(BCRC, Hsinchu City, Taiwan) and were cultured in a
keratinocyte-serum free medium (Gibco/Invitrogen) with 5 ng/
ml human recombinant epidermal growth factor and 50 mg/ml
bovine pituitary extract.
Cell Proliferation Assay
Cells were seeded at a density of 36103 cells/well in 100 ml
complete medium in 96-well plates. Proliferation assays were
performed under maintenance conditions (DMEM with 10% FBS
for PC-3 and DU-145; DMEM with 10% CS-FBS for LNCaP
CDXR-3). Relative cell number was analyzed by measuring the
DNA content of cell lysates with the fluorescent dye Hoechst
33258 (Sigma, St. Louis, MO, USA) as described previously
[8,10,11,21,23,24,27,28]. All readouts were normalized to the
average of the control condition (no triol treatment) in each
individual experiment. The experiment was repeated three times.
Ten wells were used for each condition. The mean and standard
deviation represented the average and standard deviation respec-
tively of the results from all 30 wells in the three experiments.
Cell Viability Assay
Cells were seeded at a density of 36103 cells per well in a 96-
well plate (BD Bioscience). After 24 hrs, the cells were treated with
increasing concentrations of triol for 48 hrs or 96 hrs. Cell viability
was assessed by an MTT (3,4,5-dimethylthiazol-2-yl)-2-5-diphe-
nyltetrazolium bromide) assay [29]. The amount of formazan was
determined by measuring the absorbance at 560 nm using an
Tecan GENiosTM plate reader (Tecan group Ltd, Ma¨nnedorf,
Switzerland) [29]. All results were normalized to the average of the
control condition (no triol treatment) in each individual experi-
ment. The experiment was repeated three times. Each time ten
wells were utilized for each condition. The mean and standard
deviation represented the results from all 30 wells in the three
experiments.
Flow Cytometric Analysis
Cells were seeded at a density of 56105 cells in 10-cm dishes in
10 mL of media and cultured for 24 hrs before addition of triol.
After 48 hrs of culture in the presence of various concentrations of
triol, cells were removed with trypsin and fixed in 70% ethanol in
phosphate buffered saline (PBS) overnight at 220uC. Fixed cells
were washed with PBS, treated with 0.1 mg/mL RNase A in PBS
for 30 min, and then suspended in PBS containing 50 mg/mL
Figure 2. Effect of triol on colony formation in soft agar. PC-3 (A) and LNCaP CDXR-3 (B) cells treated with 0, 10, or 20 mM triol for 14 and 17
days, respectively. Image is a representative result of three biological replicates.
doi:10.1371/journal.pone.0065734.g002
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propidium iodide. Cell cycle profiles and distributions were
determined by flow cytometric analysis of cells using a BD
Facscan flow cytometer (BD Biosciences). The cell cycle distribu-
tion was analyzed using ModFit LT software (Verity Software
House, Topsham, ME, USA) as described [10,23,24,26,27].
Soft Agar Colony Formation Assay
PC-3 and LNCaP CDXR-3 cells (86103) were suspended in
0.3% low melting agarose (Lonza, Allendale, NJ, USA) containing
DMEM with 10% FBS or 10% charcoal-stripped FBS (CS-FBS),
respectively, and then layered on top of 3 ml of solidified 0.5% low
melting agarose containing DMEMmedium with 10% FBS (PC-3)
or 10% CS-FBS (CDXR-3) in 6 cm dishes. Cells were allowed to
grow at 37uC with 5% CO2 for 14 days (PC-3) or 17 days
(CDXR-3). The plates were stained with 0.005% crystal violet in
30% ethanol for 6 hrs to detect cell colonies.
TUNEL Assay
Cells were cultured on cover slips in 24 wells and were treated
with 0, 20, and 40 mM triol for 48 or 96 hrs. Cells were rinsed
twice with PBS and subjected to the TUNEL assay using ApoAlert
DNA Fragmentation Assay Kit (catalog no. 630108 from
Clontech, Mountain View, CA, USA) according to the manufac-
ture’s instruction. The TUNEL-stained cells were observed with
Olympus confocal microscope at 2006 (FV300, Olympus, Tokyo,
Japan).
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health (Taiwan).
The protocol was approved by the National Health Research
Institutes Institutional Animal Care and Use Committee (NHRI-
Figure 3. Effect of triol on the growth of PC-3 xenografts in nude mice. Male Balb/c nu/nu mice, 6–8 weeks of age, were injected
subcutaneously in both flanks with 56105 PC-3 cells suspended in 0.5 ml of Matrigel. Tumors were measured daily using calipers and volume was
calculated using the formula volume= length6width6height60.52. Monitoring of tumor growth was started one week after tumor inoculation. Mice
were separated into control and treatment groups. The control group had 5 mice carrying 10 tumors and the treatment group had 5 mice carrying 8
tumors. Three weeks after the initial inoculation, the treatment group was orally administrated triol daily at a dose of 20 mg/kg, 5 days/week. Mice in
the control group were gavaged with vehicle only. Treatment started on day 22 and ended on day 42 after tumor inoculation. Tumor volumes were
shown as mean 6 standard error (A) while body weight of mice was shown as mean 6 Standard Deviation (B).
doi:10.1371/journal.pone.0065734.g003
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Figure 4. Effect of triol on cell cycle distribution of prostate cancer cells. LNCaP CDXR-3 (A) and DU-145 cells (B) were treated with 0 or
10 mM triol for 48 hrs. PC-3 cells (C) were treated with 0, 10, or 20 mM triol for 48 hrs. (D) DU-145 cells were treated with 0, 20, and 40 mM triol for
48 hrs. Cell cycle distribution was determined by flow cytometry. Asterisk (*, **, ***) represents statistically significant difference (p,0.05, p,0.01, and
p,0.001, respectively) between the treated group and the control group.
doi:10.1371/journal.pone.0065734.g004
Figure 5. Triol induces apoptosis in prostate cancer cells. LNCaP CDXR-3, DU-145, and PC-3 cells were treated with 0, 20, and 40 mM
triol for 48 hrs. Cell morphology was determined by light microscopy. TUNEL assay was performed as described in Materials and Methods to
determine the apoptotic cell population. Green fluorescent light indicated apoptotic cells stained with TUNEL assay. Images were viewed at 2006
with Olympus confocal microscope.
doi:10.1371/journal.pone.0065734.g005
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IACUC-101046-A). Mice were kept under controlled environ-
mental conditions (22uC, 12 hrs alternate light-dark cycles, 50%
humidity, food and water ad libitum). Anesthesia (Isoflurane 1%)
was given to reduce pain in mice during inoculation of prostate
cancer cells. Animal care was conducted in accordance with the
standard ethical guidelines (National Institutes of Health’s ‘‘Guide
for the care and use of Laboratory animals’’ and Clinical
laboratory animal medicine (K. Hrapkiewicz, L. Medina, and
D.D. Holmes, 1998, Iowa State University Press). The experiment
was designed to minimize the number of nude mice used.
Tumor Xenografts in Athymic Mice
Experiments involving mice were approved by National Health
Research Institutes Institutional Animal Care and Use Committee
(NHRI-IACUC-101046-A). Male Balb/c nu/nu mice (NCI
Frederick, MD), 6–8 weeks of age, were injected subcutaneously
in both flanks with 56105 PC-3 cells suspended in 0.5 ml of
Matrigel (BD Bioscience, Franklin Lakes, NJ, USA). Monitoring of
tumor growth was started one week after tumor inoculation. Mice
were separated into control and treatment groups. 5 mice carrying
10 tumors comprised the control group and 5 mice carrying 8
tumors comprised the treatment group. Three weeks after
inoculation of PC-3 cells, mice in the treatment group were
treated orally 5 days/week with 20 mg/kg triol. Triol was
administered in a vehicle containing 1% Tween 20, 25%
dimethylsulfoxide in PBS. Mice in the control group were gavaged
with vehicle only. Triol treatment was started 21 days after
inoculation of cells and continued for 21 days. Tumors were
measured weekly using calipers and volume was calculated using
the formula volume= length6width6height60.52 [7,21–23].
Figure 6. Micro-Western Array analysis of protein expression in CDXR-3, DU-145, and PC-3 cells treated with 0 or 20 mM triol. CDXR-
3, DU-145, and PC-3 cells were treated with 0 or 20 mM of triol for 48 hrs. Cell lysates were collected according to Micro-Western Array (MWA)
protocol [18] and MWAs were performed to measure the changes in abundance and modification of indicated proteins. The six samples printed in
each well from left to right were CDXR-3 (control), CDXR-3 (20 mM triol), DU-145 (control), DU-145 (20 mM triol), PC-3 (control), PC-3 (20 mM triol)
(Figure S2). The right half blot (well A7-H12) was the technical duplicate of the left half blot (well A1-H6). Antibody list is shown in Table S2. Red and
green were artificial color for anti-rabbit and anti-mouse 2nd antibody, respectively. The blot is the same size as a standard 96-well microtiter plate.
Relative protein abundance of each signaling protein in each cell line is listed in Table S3.
doi:10.1371/journal.pone.0065734.g006
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Luciferase-reporter Assay
PC-3 cells were seeded at 26105 cells/well in a 12-well plate in
DMEM containing 10% FBS. 24 hrs after plating, PC-3 cells were
transfected with pRL-TK-Renilla luciferase plasmid (normaliza-
tion vector; 5 ng/well), pSG5RXRa and pSG5LXRa (400 ng/
well ), 4xDR4D56cfos pGL3 (reporter gene vector; 500 ng/well)
using the PolyJetTM in vitro DNA transfection reagent (SigmaGen
Laboratories, Rockville, MD, USA). 24 hrs after transfection, cells
were treated with increasing concentrations of triol or T0901317.
After an additional 24 hrs, cells were lysed in 100 ml passive lysis
buffer (Promega, Madison, WI, USA) and luciferase activity was
measured using a Dual-Luciferase kit (Promega) in a 20/20n
luminometer Turner Biosystems.
Western Blotting Analysis
Cells samples were lysed in SDS lysis buffer (240 mM Tris-
acetate, 1% SDS, 1% glycerol, 5 mM EDTA pH 8.0, 0.1 mM
dithiothreitol) containing the protease inhibitors 1 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride (AEBSF), 0.8 mM aprotinin,
40 mM bestatin, 14 mM E-64, 20 mM leupeptin, 15 mM Pepstatin
A (Sigma-Aldrich, P8340) and the phosphatase inhibitors
cantharidin, bromotetramisole and microcystin LR (Sigma-
Aldrich, P2850). Tissues samples were prepared from tissue
homogenized in 26Laemmli buffer as previously described [7,21–
24]. Expression of proteins including Akt1, Skp2, phospho-Akt
Ser473, phospho-Akt Thr308, PDK1, phospho-p44/42 MAPK
Thr202/Tyr204, CDK2, CDK6, fatty acid synthase (FASN),
GSK-3a, GSK-3b, Rb, cyclin B1, cyclin D1, phospho-p38 MAPK
Thr180/Tyr182, phospho-PDK1 Ser241, phospho-Rb Ser780,
FAK, and MMP9 was detected using antibodies from Cell
Signaling Technology (Danvers, MA, USA). E-cadherin, N-
cadherin, and p27Kip1 antibodies were from BD BioSciences
(San Jose, CA, USA). Antibodies for detection of c-Myc, caspase 3,
caspase 8, caspase 9, PTEN were from Epitomics (Burlingame,
CA, USA). Slug antibody was purchased from Abgent (San Diego,
CA, USA). Vimentin antibody was from Thermo (Waltham,
Massachusetts, USA). The antibodies against Akt1, Akt2, Akt3,
Bcl-2, P53, Cdk4, NF-kB, cyclin A, cyclin E1, cyclin E2, E2F-1,
phospho-GSK-3a Ser21, phospho-GSK-3b Ser9, phospho-c-Myc
Thr58/Ser62, phospho-PTEN Ser385, phospho-FAK Ser722,
phospho-FAK Tyr861, and a-tubulin were from Millipore (Bill-
erica, MA, USA). Antibodies detecting a-tubulin, b-actin, and
GAPDH were purchased from Novus (Littleton, CO, USA).
Antibodies for Skp2, p21Cip, and p27Kip were from Santa Cruz
(Dallas, TX, USA). Horseradish peroxidase-conjugated anti-rabbit
and anti-mouse IgG secondary antibodies were from Santa Cruz.
The signal of horseradish peroxidase labeled secondary antibodies
was detected by enhanced chemoluminescence reaction (ECL
Western Blotting detection kit) (PerkinElmer, Waltham, MA,
USA). GAPDH, a-tubulin, and b-actin were used as loading
controls.
Micro-Western Arrays
CDXR-3 and DU-145 cells were treated with vehicle (DMSO)
or 10 mM triol for 48 hrs. Micro-Western Arrays were performed
to measure protein expression and modification as previously
described [17,18,20,24].
Skp2 Overexpression in PC-3 Cells
Ectopic expression of Skp2 was achieved by infecting PC-3 cells
with a retrovirus generated from the LPCX plasmid containing
wild-type human Skp2 cDNA as described [10]. Puromycin-
resistant colonies were expanded and screened for increased Skp2
Figure 7. Protein expression profile of Micro-Western Array
results. Protein expression profiles of CDXR-3, DU-145, and PC-3 cells
treated with triol are displayed in a heat map format. Black color
indicated no change, while green and red colors indicated decrease and
increase of protein expression level. Grey color indicated signal below
detection threshold. Protein abundance was normalized to the average
of a-tubulin, GAPDH, and b-actin. Proteins in different cell lines were
normalized to the control condition (no triol treatment) of that cell line.
doi:10.1371/journal.pone.0065734.g007
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Figure 8. Effect of triol treatment on the abundance and phosphorylation status of signaling proteins. Protein expression of Akt1,
phospho-Akt Thr308, phospho-Akt Ser473, PDK1, phospho-p44/42 MAPK Thr202/Tyr204, c-Myc, Skp2, p27Kip1, FASN, GAPDH, b-actin, and a-tubulin in
CDXR-3, DU-145, and PC-3 cells treated with 0, 10 or 20 mM triol for 48 hrs were assayed by Western blotting. Values represent relative protein
abundance.
doi:10.1371/journal.pone.0065734.g008
Cholestane Triol for Prostate Cancer Treatment
PLOS ONE | www.plosone.org 8 June 2013 | Volume 8 | Issue 6 | e65734
protein expression by Western blot analysis. PC-3 cells infected
with an empty LPCX retrovirus were used as controls [10]. Cells
were lysed in Laemmli buffer without bromophenol blue dye.
Real-Time Quantitative Polymerase Chain Reaction
RNA was extracted from the PC-3 and DU-145 cells treated
with 0, 10, and 20 mM triol for 48 hrs using the RNeasy Minikit
(cat. No. 74104, Qiagen, Venlo, The Netherlands) following the
manufacturer’s instructions. The genomic DNA was removed by
DNase-on-column treatment supplied with the mini kit. RNA
concentration was determined spectrophotometrically at 260 nm.
Equal amounts of RNA were used in the cDNA synthesis reactions
using the Reverse Transciption SystemRevertAidTM H Minus
First Strand cDNA Synthesis Kit (Fermentas/Thermo Scientific,
Waltham, MA, USA). Real-time quantitative PCR was performed
as previously described [7,8,21–23,28] using SYBR Green system/
’reagents in an optical 96-well plate and cycling conditions
consisting of 2 min at 50uC, 10 min st 95uC, 40 cycles of 15 sec at
95uC, and 60 sec at 60uC on an ABI Prism system (Applied
Biosystems, Foster City, CA, USA). The sequences of primers for
ATP-binding cassette transporter A1 (ABCA1) were
TGTCCAGTCCAGTAATGGTTC (forward) and AAGCGA-
GATATGGTCCGGATT (reverse). The transcript level of
ABCA1 was determined in PC-3 and DU-145 cells following
treatment with 0, 10, and 20 mM triol for 48 hrs and was
normalized to GAPDH levels in each sample.
Transwell Migration Assay
Migration assays with PC-3 cells were performed with a
transwell kit from BD Bioscience (catalog number 353097). PC-
3, DU-145, and CDXR-3 cells were treated with 0, 10, and
20 mM triol for 48 hrs. Cells were then removed from tissue
culture plates with trypsin, and washed twice with PBS. Triol-
treated cells (16104) in 250 ul of DMEM without serum were
placed in the upper invasion chamber and the lower compartment
was loaded with DMEM containing 10% FBS. The cell migration
chamber was inserted into the lower compartment and incubated
for either 6 (PC-3, DU-145) or 24 (CDXR-3) hrs at 37uC. Cells on
the topside of the filter were removed with a cotton swab. Cells
attached to the filter were then fixed with methanol for 10 min.
Cells attached to the filter were then stained with Giemsa stain
(5%) for 1 hour. Filters were de-stained by washing with water and
the number of cells attached to the filter was then quantified by
enumerating cells in photographs of the stained filters.
Transwell Invasion Assay
An invasion assay with PC-3 cells was performed with Growth
Factor Reduced BD BioCoat Matrigel invasion chambers (BD
Biosciences) according to the manufacturer’s instructions. PC-3
cells were treated with different concentrations of triol for 48 hrs.
Cells were then trypsinized and washed twice with PBS. Cells from
each condition were seeded at 46104 cells per well in serum-free
DMEM in the upper compartment, and DMEM medium with
10% FBS was placed in the lower compartment of the chamber as
a chemo-attractant. After 24 hrs of incubation, the non-invading
cells on the upper side of the chamber were removed, and the
membranes were fixed with methanol, washed, and stained with
Giemsa’s solution. Invasiveness was evaluated by counting the
invading cells under a light microscope. All experiments were
conducted in triplicate.
Wound Healing Assay
CDXR-3 cells were pre-treated with 0, 10, and 20 mM triol for
24 hrs. Cells were then removed from tissue culture plates with
trypsin, and washed twice with PBS. Cells were seeded at a
concentration of 3.56104 cells/well in 12-well plates. After 24 hrs,
a wound healing assay was performed by scraping the cells with a
200-ml pipette tip. Cells were observed at 0, 8, and 24 hrs after
scraping and photographed with a live imaging microscope (Leica
AF 6000 LX, Leica, Wetzlar, Germany). The migration distance
was automatically measured by the program inside live imaging
microscope.
Confocal Microscopy
CDXR-3 and DU-145 cells were treated with 0 or 10 mM triol
for 24 hrs. Cells were then washed 3 times with PBS buffer for
5 min per wash at room temperature (RT), fixed with 4%
paraformaldehyde for 15 min at RT, and rinsed with PBS 3 times
Figure 9. Effect of overexpression of Skp2 protein on growth
inhibition by triol treatment. (A) Protein expression of Skp2 assayed
by Western blotting in PC-3 LPCX control and PC-3 LPCX Skp2 cell lines.
PC-3 cells overexpressing Skp2 with LPCX vector and control PC-3 cells
(empty LPCX vector) were treated with increasing concentrations of
triol for 48 hrs (B) or 96 hrs (C) and analyzed by the 96-well proliferation
assay. Asterisk * and *** represent statistically significant difference
(p,0.05 and p,0.001) between the PC-3 control cells and PC-3
overexpressing Skp2- cells.
doi:10.1371/journal.pone.0065734.g009
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for 5 min per wash and permeabilized for 10 minutes at RT with
0.1% Triton X-100 in PBS. Cells were blocked for non-specific
protein binding with 2% bovine serum albumin in PBS for
30 min, rinsed with PBS three times for 5 min each. Cells were
incubated with b-actin or a-tubulin antibody for one hour. After
washing, cells were incubated with secondary FITC-conjugated
antibody for one hour. After washing, cells were mounted under
glass slides and sealed with Permount. Images of cells were
observed with an Olympus confocal microscope at 4006 (ocular
lens 106; objective lens 406) (FV300, Olympus, Tokyo, Japan).
Data Analysis
Data are presented as the mean +/2 SD of at least three
experiments or are representative of experiments repeated at least
three times. Student’s t test (two-tailed, unpaired) was used to
evaluate the statistical significance of results from the proliferation
assay experiments. A Microsoft Excel add-in program ED50V10
was used for calculating half maximal effective concentration
(EC50).
Results
Triol Suppressed the Proliferation of Human Prostate
Cancer Cells
We first sought to determine the effect of triol treatment on the
viability and proliferation of three commonly used human prostate
cancer cell lines (Fig. 1). LNCaP CDXR-3 cells are androgen
receptor (AR)-positive, relapsed, androgen-independent cells
derived from parental AR-positive androgen-dependent LNCaP
104-S cells [27]. DU-145 and PC-3 both are AR-negative
androgen-insensitive cells established from brain- [30] and bone-
[31] derived metastasis, respectively. An MTT assay and a
Hoechst dye-based proliferation assays indicated that triol
suppressed both cell viability and cellular proliferation (Fig. 1).
The inhibitory effect on proliferation was dose-dependent and
increased over time (Fig. 1, Table S1). The EC50 for triol in the
MTT assay was similar to the EC50 measured by Hoechst dye-
based proliferation assay (Table S1), suggesting that inhibition of
cell proliferation was responsible for the reduction of viable cells
caused by triol treatment in all three human advanced prostate
cancer cell lines.
Triol Treatment Inhibited Colony Formation of PC-3 and
CDXR-3 Cells in Soft Agar
Treatment of PC-3 and LNCaP CDXR-3 cells with 25 mM and
50 mM triol markedly inhibited the formation of PC-3 and LNCaP
CDXR-3 colonies in soft agar, confirming the anti-cancer activity
of triol. DU-145 cells grew too slowly in soft agar to detect
sufficient colonies for further analysis (Fig. 2).
Triol Treatment Retarded Growth of Androgen-
insensitive Prostate Cancer Xenografts in Nude Mice
To determine if triol could suppress tumor growth in vivo, we
performed a pilot study using DU-145 xenografts in nude mice.
Intraperitoneal (i.p.) injection of 1 mg (50 mg/kg) of triol daily for
14 days caused a 36% reduction in the average volume of DU-145
xenografts growing in nude mice (Fig. S1). Triol treatment for 14
days did not affect the body weight of the mice (data not shown).
To determine if lower oral doses of triol could inhibit the growth of
PC-3 prostate xenografts. we orally administered triol at 20 mg/kg
five times a week. Oral administration of 20 mg/kg triol (5 times
per week) from the 3rd to 6th week caused a 65% reduction in
average tumor volume (p= 0.0002) in the treatment group
compared to tumor volume in the vehicle control group
(Fig. 3A). Body weight of both vehicle and triol-treated groups
gradually decreased (Fig. 3B). This may be due to cachetic effects
of PC-3 xenografts. These observations confirmed that oral
administration of triol could retard the growth of prostate tumors
in vivo.
Triol Treatment Caused G1 Cell Cycle Arrest in Prostate
Cancer Cells
We next performed flow cytometric analysis to determine if cell
cycle progression of prostate cancer cells was affected by triol.
Treatment with 10 mM triol for 48 hrs caused an increase in the
G1 phase cell population and a decrease in S and G2/M phase
populations of LNCaP CDXR-3 and DU-145 prostate cancer cells
Figure 10. Triol treatment affected expression of Akt1 protein in PC-3 xenografts. (A) Protein expression of Akt1, c-Myc, FASN, Ki-67, and
a-tubulin was examined in 5 PC-3 tumors from control group and 8 PC-3 tumors from treatment group (Fig. 3). (B) Relative protein abundance of
each signaling protein was quantified and calculated for average and standard deviation. Asterisk *** represents statistically significant difference
(p,0.001) between the control and triol treatment group.
doi:10.1371/journal.pone.0065734.g010
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(Fig. 4A, 4B). Triol at 10 mM did not affect cell cycle progression
of PC-3 cells. However, 20 mM triol caused a significant increase
in G1 and decrease in the S and G2/M populations of PC-3 cells
(Fig. 4C). Therefore, treatment with 10–20 mM triol induced G1
cell cycle arrest in LNCaP, DU-145, and PC-3 cells. We did not
observe any increase in sub-G1 population in these three prostate
cancer cell lines. To determine if higher concentrations of triol will
augment the population of cells in sub-G1, we treated DU-145
cells with 0, 20, and 40 mM triol (Fig. 4D). Reduction of S phase
population and induction of G1 phase population of DU-145 cells
was even more significant after treatment with 40 mM triol.
However, there was no significant increase of cells in the sub-G1
population.
Treatment with High Concentration of Triol Induced
Apoptosis in Prostate Cancer Cells
As propidium iodide staining flow cytometric analysis is not a
reliable method to detect apoptosis, we used the TUNEL assay to
determine if triol treatment at higher concentrations induced
apoptosis in prostate cancer cells. We treated CDXR-3, DU-145,
and PC-3 cells with 0, 20, and 40 mM triol for 48 or 96 hrs.
Consistent with the flow cytometry analysis data, treatment with
triol for 48 hrs only produced a small population of apoptotic cells
in all these cell lines (data not shown). Treatment with triol for
96 hrs dose-dependently resulted in an increased the population of
apoptotic cells in all three prostate cancer cell lines (Fig. 5).
Although treatment with 20 mM triol for 96 hrs only slightly
increased the apoptotic population, treatment with 40 mM triol
resulted in a significant increase in apoptosis in all three prostate
cancer cell lines.
Micro-Western Array Revealed Signaling Proteins being
Affected by Triol Treatment
We hypothesized that triol may reduce cell viability through its
effect on protein signaling networks. In order to determine what
signaling proteins might be affected by triol treatment, we used
Micro-Western Arrays (MWAs), a high-throughput Western
blotting assay [17–20,24], to screen for signaling proteins affected
by treatment with 10 mM triol in CDXR-3 and DU-145 cells.
PTEN is frequently deleted in prostate cancer, resulting in
activation of PI3K/Akt signaling [32]. PI3K/Akt signaling plays
an important role in survival and progression of prostate cancer
cells [32,33]. Up-regulation of PI3K/Akt activity is associated with
poor clinical outcome of prostate cancer [34]. We used 48
antibodies that are capable of detecting proteins regulating cell
cycle progression, cell survival and apoptosis, Akt-related signaling
pathways, and several epithelial-mesenchymal transition (EMT)
markers (Figure S2, Table S2) for the screening portion of our
MWA study (Fig. 6). Differences in the protein expression profile
in the absence and presence of 20 mM triol is shown in Fig. 7.
Each of the three cell lines had a unique protein expression
response to triol treatment. The protein profiles of CDXR-3 and
PC-3 cells following treatment with 20 mM triol were more similar
to each other than to DU-145 cells. Triol caused reduction of
Akt1, cyclin E2, cyclin B1, phospho-c-Myc Thr58/Ser62, c-Myc,
and phospho-Akt Ser473 in all three prostate cancer cell lines.
Triol treatment at 20 mM resulted in at least a 20% increase in the
protein abundance of phospho-p38 MAPK Thr180/Tyr182
(CDXR-3), CDK4 (DU-145), cyclin E1 (DU-145), cyclin D1
(DU-145), and p53 (PC-3); but caused at least a 20% decrease in
the protein abundance of cyclin D1 (CDXR-3), phospho-c-Myc
Thr58/Ser62 (CDXR-3), phospho-Rb Ser780 (CDXR-3), c-Myc
(CDXR-3, PC-3), phospho-Akt Thr308 (CDXR-3, PC-3), phos-
pho-Akt Ser473 (DU-145, PC-3), cyclin A (DU-145), cyclin B1
(DU-145, PC-3), phospho-GSK3a Ser21 (DU-145), NF-kB p65
(PC-3), and fatty acid synthase (FASN) (PC-3) (Table S3).
Triol Decreased the Level or Phosphorylation Status of
Signaling Proteins Involved in Cell Cycle and Akt
Signaling
The MWA result suggested that triol treatment altered the
abundance and phosphorylation status of signaling proteins
involved in cell cycle and Akt signaling in prostate cancer cells.
We performed conventional Western blotting analysis to confirm
these results. Triol treatment caused a decrease of Akt1 (DU-145,
CDXR-3), phospho-Akt Thr308 (DU-145), phospho-Akt Ser473
(DU-145, CDXR-3, PC-3), PDK1 (DU-145, CDXR-3, PC-3),
phospho-p44/42 MAPK Thr202/Tyr204 (DU-145, CDXR-3,
PC-3), c-Myc (DU-145, CDXR-3), and S-phase kinase-associated
protein 2 (Skp2) (DU-145, CDXR-3, PC-3). Triol treatment also
resulted in elevated cell cycle inhibitor p27Kip in all three cell lines.
FASN expression was slightly increased in DU-145 but slightly
decreased in CDXR-3 and PC-3 cells treated with triol (Fig. 8).
Figure 11. Effect of triol on LXR reporter and ABCA1 gene
expression. (A) PC-3 cells were transfected with pRL-TK-Renilla
luciferase plasmid, pSG5RXRa, pSG5LXRa, and 4xDR4D56cfos pGL3
reporter gene plasmid. PC-3 cells were treated with 0, 5, 10, 20 mM triol
or 1 mM T0901317. Luciferase reporter gene assay was performed to
determine the activity of LXRa receptor. (B) PC-3 and DU-145 cells were
treated with 0, 10, 20 mM triol for 48 hrs. ABCA1 gene, a target gene of
LXRa, was determined by qRT-PCR. Asterisk * represents statistically
significant difference (p,0.05) between the control and triol treatment
group.
doi:10.1371/journal.pone.0065734.g011
Cholestane Triol for Prostate Cancer Treatment
PLOS ONE | www.plosone.org 11 June 2013 | Volume 8 | Issue 6 | e65734
Overexpression of Skp2 Partially Rescued the Inhibitory
Effect of Triol Treatment in PC-3 Cells
Since triol treatment caused a significant decrease in Skp2
expression and an increase in p27Kip expression in all three
prostate cancer cell lines (Fig. 8), we next wished to determine if
overexpression of Skp2 would block the growth inhibition caused
by triol in PC-3 cells. Indeed, overexpression of Skp2 partially
rescued the cell proliferation rate of PC-3 cells under triol
treatment (Fig. 9). Because overexpression of Skp2 did not
Figure 12. Effect of triol treatment on cytoskeleton morphology in CDXR-3 and DU-145 cells. Imaging of a-tubulin and b-actin in CDXR-3
and DU-145 cells treated with vehicle or 10 mM triol for 48 hrs was determined by confocal microscopy.
doi:10.1371/journal.pone.0065734.g012
Figure 13. Effect of triol treatment on migration and invasion of PC-3, DU-145, and CDXR-3 cells. PC-3, DU-145, and CDXR-3 cells were
pre-treated with 0, 10, or 20 mM triol for 48 hrs. Cells were then counted and seeded at identical number. Cancer cell migration ability (A) and
invasion ability (B) was determined by transwell migration assay (A) and transwell invasion assay 6 hrs (A) and 24 hrs (B) after cell seeding,
respectively. (C) Migration of CDXR-3 cells was determined by transwell migration assay 24 hrs after cell seeding. There was no triol in medium during
the migration or invasion assay. Asterisk *** represents statistically significant difference (p,0.001) between the control group and triol treatment
group.
doi:10.1371/journal.pone.0065734.g013
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completely reverse the growth inhibitory effects, we hypothesized
that other additional pathways or mechanisms may be influenced
by triol to cause cell growth inhibition of prostate cancer cells.
Triol Treatment Suppressed Akt1 in PC-3 Xenograft
We examined the protein expression of Akt1, c-Myc, FASN, Ki-
67, and a-tubulin in 5 tumors xenografts from the vehicle-treated
group and 8 tumor xenografts from the triol-treated group from
Fig. 3. Triol treatment resulted in significantly reduced Akt1
expression in PC-3 xenografts (p,0.001, Fig. 10). Tumors in the
treatment group tended to express lower c-Myc and FASN levels,
although the p value was larger than 0.05. We also determined the
protein levels of E-cadherin, N-cadherin, MMP-9, vimentin, slug,
snail, p27Kip, and phospho-Akt Ser473 in these xenografts. The
variation between individual tumors within both control and
treatment groups of these proteins was large and no significant
difference in specific protein abundances between control and
treatment groups (data not shown).
Triol is as a Weak Liver X Receptor (LXR) Agonist
LXRs are ligand-activated transcriptional factors that belong to
the nuclear receptor super family. LXRs are important regulators
of cholesterol, fatty acid, and glucose homeostasis [9]. Two LXR
isoforms exist: LXRa expression is most abundant in liver, kidney,
intestine, fat tissue, macrophages, lung, and spleen; LXRb is
expressed ubiquitously [9]. A specific group of oxysterols,
including 22(R)-hydroxycholesterol, 20(S)-hydroxycholesterol,
24(S)-hydroxycholesterol, and cholestenoic acid are natural ligands
for LXRs [9,10]. We previously reported that LXR agonists, such
as T0901317, 22(R)-hydroxycholesterol, and 24(S)-hydroxycho-
lesterol suppress the proliferation of prostate and breast cancer
cells via induction of G1 cell cycle arrest [6–10]. Since triol is an
oxysterol, it might produce some effects as an agonist for LXR. To
determine if triol is an LXR agonist, we determined if triol could
activate LXR and induce expression of a luciferase reporter gene
containing a LXR response element. Triol only slightly increased
the transcriptional activity of LXRa (Fig. 11A). However,
compared to the well known LXR agonist T0901317, triol was
a very weak LXRa agonist (Fig. 11A). Treatment of DU-145 cells
Figure 14. Triol treatment inhibited migration of CDXR-3 cells determined by wound healing assay. Wound healing assay was
performed to determine the effect of (A) 0 mM (B) 10 mM or (C) 20 mM triol on migration ability of CDXR-3 cells 8 or 24 hrs after cell seeding. (D)
Results of (A)(B)(C) were quantified. Asterisk * and ** represents statistically significant difference (p,0.05 and p,0.01) between the control group
and the triol treatment group.
doi:10.1371/journal.pone.0065734.g014
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with 20 mM triol resulted in a slight increase in expression of
ABCA1 mRNA expression, a target gene of LXRa activity
(Fig. 11B), confirming the agonistic activity of triol for LXRa. The
agonistic activity of triol for LXRa may partially contribute to the
growth inhibition and G1 cell cycle arrest of prostate cancer cells.
Triol Treatment Altered Actin and Tubulin Distribution in
Prostate Cancer Cells
Triol was previously reported to cause disruption of actin
microfilaments [35], redistribution of vimentin [36], and loss of
vinculin [35] in 73/73 endothelial cells. We next sought to
determine if the cytoskeleton was affected by triol treatment of
prostate cancer cells. Confocal laser microscopy revealed a
modification of the b-actin and a-tubulin microfilaments, espe-
cially redistribution at the periphery of the cells following 48 hrs of
treatment with 10 mM triol in CDXR-3 and DU-145 cells (Fig. 12).
We did not observe significant changes in b-actin and a-tubulin
microfilaments in PC-3 cells treated with 10 mM triol (data not
shown).
Figure 15. Effect of triol on expression levels of EMT marker and FAK proteins in PC-3, DU-145, and CDXR-3 cells. Protein expression
of E-cadherin, N-cadherin, vimentin, Slug, FAK, phospho-FAK Ser722, phospho-FAK Tyr861, b-actin, and a-tubulin in PC-3, DU-145, and CDXR-3 cells
treated with 0, 10, or 20 mM triol for 48 hrs were assayed by Western blotting. Values represent relative protein abundance.
doi:10.1371/journal.pone.0065734.g015
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Triol Treatment Suppressed Migration and Invasion of
Prostate Cancer Cells
Since triol resulted in changes in the structure and morphology
of the cytoskeleton, we suspected that triol treatment might affect
the migration and invasion of prostate cancer cells. Pre-treatment
of prostate cancer cells with 10 mM or 20 mM triol for 48 hrs
significantly inhibited the migration and invasiveness of DU-145
and PC-3 cells (Fig. 13A, 13B). LNCaP cells have poor migration
and invasion ability. Extending the time for transwell migration
assay revealed that migration of LNCaP CDXR-3 was suppressed
dose-dependently by triol treatment (Fig. 13C). A wound healing
assay confirmed that treatment with 20 mM triol significantly
reduced the migration ability of LNCaP CDXR-3 cells (Fig. 14).
Triol Treatment Affected Epithelial-mesenchymal
Transition Proteins in Prostate Cancer Cells
Epithelial-mesenchymal transition (EMT) marker proteins
regulate the ability of cancer cells to migrate and invade. We
determined if triol treatment altered the expression level of these
EMT marker proteins. Triol treatment (20 mM) resulted in
increased E-cadherin protein abundance (DU-145, CDXR-3),
N-cadherin (PC-3 cells), and phospho-focal adhesion kinase (FAK)
Ser722/Tyr861 (CDXR-3) cells. Triol treatment (20 mM) resulted
in decreased protein levels of N-cadherin (DU-145, CDXR-3),
vimentin (PC-3, CDXR-3), Slug (DU-145, CDXR-3), FAK (PC-3,
DU-145), phospho-FAK Ser722 (DU-145), and phospho-FAK
Tyr861 (PC-3, DU-145). (Fig. 15).
Non-cancerous Human Prostate Epithelial Cells were
More Resistant to Triol Treatment
We sought to determine the effect of triol on the proliferation of
non-cancerous human cells. In place of normal prostate epithelial
cells, we used PZ-HPV-7 cells. PZ-HPV-7 cells were derived from
normal human prostate epithelial cells transformed by transfection
with HPV18 DNA. Compared to the three prostate cancer cell
lines in this study, PZ-HPV-7 cells were more resistant to triol
treatment. After 48 hrs treatment with triol, the EC50 for triol
suppression of proliferation of PZ-HPV-7 cells was 110.5 mM
(Fig. 16). This suggested the possibility that non-cancerous human
prostate cells may be more resistant to triol treatment compared to
prostate cancer cells. However, the higher resistance of PZ-HPV-7
cells to triol treatment might be due to the lower proliferation rate
of these non-cancerous cells compared to that of cancer cells.
Further studies are needed to determine if triol will adversely affect
normal prostate cells.
Discussion
Oxysterols are more polar and more readily diffusible through
cell membranes than cholesterol, and possesses higher pro-
inflammatory and cytotoxic effects than cholesterol in certain
cells and tissues [13,37]. Oxysterols have been reported to be
potentially involved in the initiation and progression of athero-
sclerosis, neurodegeneration, diabetes, kidney failure, and ethanol
intoxication [13]. In cholesterol-rich foods, the most commonly
found oxysterols include 7a-hydroxycholesterol, 7b-hydroxycho-
lesterol, 7-ketocholesterol, 5a,6a-epoxycholesterol, and 5b,6b-
epoxycholesterol [13]. Both 5a, 6a-epoxycholesterol and 5b, 6b-
epoxycholesterol are unstable and are converted to cholestane-3b,
5a, 6b-triol [15,16]. Oxysterols have been shown to suppress the
proliferation and survival of human cancer cells in vitro [7–14].
The cytotoxicity of oxysterols may cause growth inhibition and cell
death in cancer cells if applied locally to tumors.
We observed that triol treatment inhibited tumor growth,
reduced cell proliferation, induced G1 cell cycle arrest, and altered
cytoskeletal morphology of human prostate cancer cells. Oral
administration of triol at 20 mg/kg for three weeks reduced the
average tumor volume of AR-negative androgen-insensitive PC-3
prostate cancer cells by 65% (Fig. 3). PC-3, one of the most
commonly used prostate cancer cell lines, was established from
bone-derived metastases [31]. Prostate cancer has a predilection to
metastasize to bone and more than 80% of patients who died from
prostate cancer developed bone metastases [38–40]. Our animal
study suggested that triol treatment might be a potential treatment
for prostate cancer metastasis. Indeed, we demonstrated that triol
suppressed migration and invasion of DU-145, PC-3, and LNCaP
CDXR-3 cells. The inhibition of migration and invasion of
prostate cancer cells was not due to reduction of cell proliferation
because the triol was given as a pre-treatment only and the same
number of prostate cancer cells was seeded in both control and
pre-treatment groups for the transwell assay (Fig. 9). Cancer cells
in certain circumstance recapitulate normal developmental
processes to enhance cell migration and invasion, a procedure
called epithelial-to-mesenchymal transition (EMT). During the
EMT, polarity is lost, motility is increased, mesenchymal markers
are up-regulated, and differentiation markers are down-regulated
[41,42]. This process was linked to cancer progression, in which
epithelial cells acquire increased capacity for migration, stromal
invasion, and metastasis [41,42]. During EMT of prostate cancer
cells, the expression of transcription factors such as Snail, Slug,
Twist, E47, ZEB1, and ZEB2 is increased, which leads to
increased expression of N-cadherin and vimentin and concomi-
tantly decreased expression of E-cadherin and cytokeratins [42–
45]. Our study suggested that triol treatment resulted in decreased
abundance of the proteins Slug, vimentin, and N-cadherin
proteins while resulting in increased expression of the protein E-
cadherin protein (Fig. 10). Focal adhesion kinase (FAK) is a non-
receptor tyrosine kinase localized in focal contacts that becomes
tyrosine phosphorylated. FAK signaling pathway is involved in the
regulation of prostate cancer cell migration [46–49]. We observed
that triol treatment resulted in reduced abundance of FAK in PC-
3 cells as well as phospho-FAK Ser722 in DU-145 cells and
phospho-FAK Tyr861 in PC-3 cells. This new finding indicated
Figure 16. Effect of triol on viability of non-cancer human cell
lines. Human prostate epithelial PZ-HPV-7 cells were treated with
increasing concentrations of triol for 48 hrs. Relative cell viability was
determined by MTT assay as described in Material and Methods. Cell
numbers were normalized to control (dimethylsulfoxide treatment) for
each cell line. Asterisk * represents statistically significant difference
(p,0.05) between the treated and the control group.
doi:10.1371/journal.pone.0065734.g016
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that triol treatment targeted both EMT markers and FAK
signaling proteins and can thus be a potential therapeutic agent
for treatment of prostate cancer metastasis. We observed that non-
cancerous human prostate epithelial PZ-HPV-7 cells were more
resistant to triol treatment compared to LNCaP, DU-145, and PC-
3 prostate cancer cells (Fig. 11). This result suggested that triol has
selectivity against prostate cancer cells versus normal cells.
Micro-Western Arrays (MWAs) represent a new method for
proteomic analyses [19]. The MWA is a modification of the
antibody-based modified reverse phase protein array. A non-
contact microarray (such as the GeSim Nanoplotter), a flatbed
electrophoresis apparatus (such as the GE multiphor), and a near
infrared scanner (such as the Licor Odyssey) comprise the MWA
analysis system [18]. The MWA system allows detection of the
abundance or modification status of up to 384 different proteins
with as many as 15 samples simultaneously. The method has been
shown to be effective in characterizing the EGFR pathway under
multiple growth factor concentrations and in network modeling of
complex receptor tyrosine kinase (RTK) cross-talk after stimula-
tion [18]. The MWA has a technical advantage over other current
technologies for assaying protein modifications such as Reverse
Phase Lysate Arrays, quantitative Mass Spectroscopy, and
Luminex through its ability to efficiently and accurately measure
hundreds of chosen phosphosites simultaneously, expanding the
number of pathways surveyed in a single experiment. We applied
this technology to screen signaling proteins being affected by triol
in prostate cancer cells. In our MWA screening using 48
antibodies against proteins involved in Akt signaling and cell
cycle regulation, we observed that triol caused reduction of Akt1,
Akt2, cyclin E2, cyclin B1, phospho-c-Myc Thr58/Ser62, c-Myc,
and phospho-Akt Ser473 in all three prostate cancer cell lines.
Treatment with 20 mM triol caused at least a 20% increase in
protein abundance of the following proteins: phospho-p38 MAPK
Thr180/Tyr182, CDK4, cyclin E1, cyclin D1, and p53; while triol
decreased in protein expression of cyclin D1, phospho-c-Myc
Thr58/Ser62, phospho-Rb Ser780, c-Myc, phospho-Akt Thr308,
phospho-Akt Ser473, cyclin A, cyclin B1, phospho-GSK3a Ser21,
NF-kB p65, and FASN (Table S3). These findings were confirmed
by conventional Western blotting. Western blotting experiments
also showed that the protein levels of Akt1, phospho-Akt Ser473,
phospho-Akt Thr308, PDK1, c-Myc, Skp2 in prostate cancer cells
was decreased by triol treatment (Fig. 8). PI3K/Akt signaling plays
an important role in survival and progression of prostate cancer
cells [32,33,50]. Akt is a serine/threonine protein kinase encoded
in mammals by three unique genes: Akt1, Akt2, and Akt3 [51,52].
Akt1 is involved in cellular survival pathways and inhibits
apoptotic processes. Akt contains at least two important phos-
phorylation sites: threonine 308 and serine 473, which regulate its
activity. Phosphorylation of threonine 308 on Akt is activated by
PDK1 [53]. Phosphorylation of serine 473 is activated by mTOR
kinase, its associated protein rictor, and SIN1/MIP1 [54,55]. Up-
regulation of the PI3K/Akt activity is associated with poor clinical
outcome of prostate cancer [33,34,50]. c-Myc protein, a well-
known proto-oncoprotein, is an important transcriptional regula-
tor of the androgenic response and cell proliferation in prostate
and other cancers [25,56]. Expression of both c-Myc mRNA and
protein increase during the progression of prostate cancer [57,58].
Decrease in c-Myc protein abundance results in decreased prostate
cancer cell proliferation and tumor growth [23,25–27,59]. Forced
expression of FASN promoted proliferation while siRNA knock-
down of FASN induced apoptosis in prostate cancer cells [60].
Because triol treatment suppressed Akt1, phospho-Akt Ser473,
phospho-Akt Thr308, PDK1, c-Myc, and FASN, reduction of Akt
signaling, c-Myc, and FASN may all contribute to growth
inhibition caused by triol. The only difference in results that we
observed between MWAs and conventional Western blots was in
the detection of phospho-p44/42 MAPK Thr202/Tyr204,
possibly due to the low abundance of the Erk1/2 proteins in
these prostate cancer cells and the relatively weak signal of the
reporter antibody for this protein. Western blotting also indicated
the induction of p27Kip1 under triol treatment. The p27Kip1 is a
cell cycle inhibitory proteins and accumulation of p27Kip1 can
result in cell cycle arrest and reduced cell proliferation of prostate
cancer cells [23,26,61]. Skp2 is a member of the F-box protein
family that is responsible for ubiquitination and down-regulation
of p27Kip1 and other proteins [62,63]. Our observation that triol
treatment resulted in decreased Skp2, increased p27Kip1, and G1
cell cycle arrest was consistent with the known functions of Skp2
and p27Kip1 (Fig. 4, Fig.7, Fig. 8). Overexpression of Skp2 partially
rescued the growth inhibition induced by triol (Fig. 9), indicating
that other pathways or mechanisms, such as LXR signaling
(Fig. 11) or cytoskeletal signaling (Fig. 12), were probably involved
in the growth inhibition caused by triol in prostate cancer cells.
Our study suggested that triol treatment causes both G1 cell
cycle arrest and apoptosis (Fig. 4, Fig. 5) in CDXR-3, DU-145,
and PC-3 in vitro. Administration via gavage of 20 mg/kg/day triol
five times a week retarded the growth of PC-3 xenografts (Fig. 3).
The actual concentration of triol in serum will require further
examination. However, the fact that Ki-67 was not significantly
reduced in PC-3 tumors suggested the possibility that bioavail-
ability of triol might be poor via oral administration. Local
injection of triol might be a more efficient way to administer triol
in future studies.
Triol was found to exert oxidative stress in rat hepatocytes as
well as to increase levels of superoxide dismutase, catalase, and
glutathione peroxidase activity [64]. Components of the cytoskel-
etal network, such as the actin microfilament meshwork or
intermediate filaments, are known targets for oxidative and thiol-
depleting agents that induce cell injury. Treatments with 20 mM
triol, 7-ketocholesterol, or 25-hydroxycholesterol for 6 hrs caused
progressive disruption of actin microfilaments, loss of vinculin,
redistribution of vimentin, induction of cell detachment, and
stimulation of apoptosis in 73/73 endothelial cells [35,36]. In our
study, confocal laser microscopy revealed a modification of the b-
actin and a-tubulin microfilaments, especially redistribution at the
periphery of the cell following 48 hrs of treatment with 10 mM
triol in CDXR-3 and DU-145 cells (Fig. 8). Alterations of actin
and tubulin distribution have been reported to cause cell cycle
arrest in human cancer cells [65,66]. Abnormal distribution of
cytoskeletal components caused by triol may contribute to the
induction of cell cycle arrest in human prostate cancer cells.
Different signaling proteins in different prostate cancer cells
responded differently to triol treatment (Fig. 6–8, 15). Several
proteins in DU-145 responded oppositely to 20 mM triol treatment
compared to PC-3 and CDXR-3 cells (Fig. 7). This observation
might be due to the different characteristics of PC-3, DU-145, and
CDXR-3 cells. Although triol treatment suppressed cell prolifer-
ation, migration, invasion, and tumor growth in all three of these
different prostate cancer cells, it may target different signaling
proteins involved in the same pathways (such as Akt signaling) or
similar functions (such as regulation of cell cycle, EMT, and cell
structure) to produce similar results in different cell lines.
Conclusions
Our study provided systems-level insight into the molecular
mechanism of triol action that resulted in suppression of
proliferation, migration, and invasion of prostate cancer cells.
Our results suggested that triol might be a potential therapeutic
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agent for treatment of advanced metastatic prostate cancer. In
addition, our study highlights the power of the MWA approach for
rapidly examining the systems level impact of small molecules on
protein signaling networks and relating these changes to cell
phenotypes.
Supporting Information
Figure S1 Effect of triol on the growth of DU-145
xenografts in nude mice. Male Balb/c nu/nu mice, 6–8
weeks of age, were injected subcutaneously in both flanks with
16106 DU-145 cells suspended in 0.5 ml of Matrigel (BD
Bioscience, Franklin Lakes, NJ, USA). Tumors were measured
daily using calipers and volume was calculated using the formula
volume= length6width6height60.52. Tumor volume was al-
lowed to increase to larger than 100 mm3 before treatment
started. Both control and treatment groups had 3 mice carrying 5
tumors. Mice were given intraperitoneal (i.p.) injection of vehicle
(5% DMSO and 1% Tween 20 in water) or 1 mg triol in vehicle
daily for 14 days. Tumor volumes were shown as mean 6
Standard Error.
(TIF)
Figure S2 Arrangement of samples on blot of MWA is
shown. For left to right, there were two loading of protein
markers, CDXR-3 (control), CDXR-3 (20 mM triol), DU-145
(control), DU-145 (20 mM triol), PC-3 (control), and PC-3 (20 mM
triol). The right half blot (well A7-H12) was the technical duplicate
of the left half blot (well A1-H6).
(TIF)
Table S1 EC50 of triol to suppress viability and
proliferation of prostate cancer cells. LNCaP CDXR-3,
DU-145, and PC-3 cells treated with triol for 48 hrs or 96 hrs
were assayed with MTT assay or Hoechst dye-based proliferation
assay to determine the EC50 of triol to cause growth inhibition.
(TIF)
Table S2 List of antibodies used in the MWA study.
Information of antibodies and location of antibodies on the
antibody plate for MWA blot incubation is shown. The a-tubulin,
b-actin, and GAPDH proteins were detected as loading controls.
(TIF)
Table S3 Relative expression level of signaling proteins
in prostate cancer cells assayed with MWA. Relative
abundance of signaling proteins in CDXR-3, DU-145, and PC-3
cells treated with 0 or 20 mM triol for 48 hrs was determined by
MWA and shown as list. N/A represents signaling being too weak
to be detected. Protein abundance was normalized to the average
of a-tubulin, GAPDH, and b-actin. Proteins in different cell lines
were normalized to the control condition (no triol treatment) of
that cell line.
(TIF)
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